Supernus Pharmaceuticals to Host Webcast on Interim Data from Phase IIa Study of SPN-817 for Treatment-Resistant Seizures

May 09, 2024 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical entity focused on creating and marketing therapies for central nervous system (CNS) conditions, announced a significant event. The company will conduct a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. ET. This session aims to discuss interim findings from the open-label Phase IIa study of SPN-817, which targets treatment-resistant seizures.

For those interested, a live broadcast featuring presentation slides will be accessible through a specific webcast link, or via the Events & Presentations section on the Investor Relations page of Supernus' website at www.supernus.com/investors. After presenting the prepared remarks and an in-depth discussion of the interim trial results, the session will be open for a question-and-answer segment.

Participants are encouraged to pre-register at any time before the event. Completion of registration will provide them with a dial-in number and a unique conference code necessary to join the call. It is recommended to dial in 15 minutes before the scheduled start to ensure timely access.

Post-call, a replay will be made available on the company's Investor Relations website at www.supernus.com/investors. Additionally, the webcast and presentation slides will remain on the company’s website for a period of 60 days following the live event.

Supernus Pharmaceuticals is dedicated to developing and commercializing therapeutic solutions for a variety of central nervous system disorders. Their extensive neuroscience portfolio includes approved treatments for conditions such as epilepsy, migraines, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients undergoing levodopa-based therapy, and drug-induced extrapyramidal reactions in adults. Furthermore, the company is actively engaged in the development of a diverse array of new CNS product candidates. These potential treatments address issues such as hypomobility in PD, epilepsy, depression, and a range of other CNS disorders.